Dropout · adults aged ≥ 16 years with PTSD
Present‐centered therapy showed no clear difference in dropout compared with control conditions (low certainty).
1 finding from 1 review
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy probably leads to higher adverse events ‐ hyperpigmentation ( compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy probably leads to higher adverse events ‐ matting ( compared with placebo (moderate certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
1 finding from 1 review
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Depressive symptoms · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether psychotherapy changes attrition Timing of outcome assessment: end of treatment compared with waiting list or no treatment (very low certainty).
1 finding from 1 review
Adverse effects (not measured · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self harm ‐ frequency of self harm · patients with borderline personality disorder
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Depressive symptoms · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Psychotherapy showed no clear difference in attrition Timing of outcome assessment: end of treatment compared with treatment‐as‐usual (low certainty).
1 finding from 1 review
Adverse effects Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Psychotherapy showed no clear difference in adverse effects Timing of outcome assessment: end of treatment compared with treatment‐as‐usual (low certainty).
1 finding from 1 review